Acumen Pharmaceuticals reported net income of -$32.75M for the quarter ended Jun 2026. This income statement covers 25 quarters of results from Jun 2020 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Jun2020 | Sep2020 | Dec2020 | Mar2021 | Jun2021 | Sep2021 | Dec2021 | Mar2022 | Jun2022 | Sep2022 | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 40.47M | 20.06M | 40.47M | 40.50M | 40.50M | 41.03M | 41.03M | 41.03M | 57.91M | 57.91M | 60.08M | 60.08M | 60.08M | 60.09M | 60.57M | 60.57M | 60.57M | 60.58M | 72.23M | 72.31M | |||||
| Operating items | |||||||||||||||||||||||||
| Research & DevelopmentR&D | 1.80M | 5.67M | 5.99M | 7.32M | 8.31M | 10.75M | 8.71M | 9.13M | 11.18M | 13.29M | 12.45M | 19.53M | 27.25M | 34.57M | 25.27M | 37.12M | 21.97M | 20.53M | 16.48M | 27.81M | |||||
| Selling, General & AdministrativeSG&A | 2.13M | 2.74M | 3.22M | 3.09M | 3.06M | 3.50M | 4.42M | 4.34M | 4.86M | 5.19M | 5.33M | 4.85M | 5.02M | 5.03M | 5.10M | 4.62M | 4.54M | 4.67M | 4.67M | 4.75M | |||||
| Operating ExpensesOpex | 3.94M | 8.41M | 9.21M | 10.41M | 11.37M | 14.25M | 13.13M | 13.48M | 16.04M | 18.49M | 17.77M | 24.38M | 32.27M | 39.60M | 30.37M | 41.75M | 26.51M | 25.20M | 21.15M | 32.56M | |||||
| Operating IncomeOp. Inc | -3.94M | -8.41M | -9.21M | -10.41M | -11.37M | -14.25M | -13.13M | -13.48M | -16.04M | -18.49M | -17.77M | -24.38M | -32.27M | -39.60M | -30.37M | -41.75M | -26.51M | -25.20M | -21.15M | -32.56M | |||||
| EBIT | -3.94M | -8.41M | -9.21M | -10.41M | -11.37M | -14.25M | -13.13M | -13.48M | -16.04M | -18.49M | -17.77M | -24.38M | -32.27M | -39.60M | -30.37M | -41.75M | -26.51M | -25.20M | -21.15M | -32.56M | |||||
| Non-operating items | |||||||||||||||||||||||||
| Non Operating Interest Expenses | 0.02M | 0.58M | 1.00M | 1.00M | 1.03M | 1.04M | 1.02M | 1.05M | 1.07M | 1.09M | 1.07M | 1.09M | |||||||||||||
| Interest & Investment IncomeInt & Inv Inc | 0.01M | 0.06M | 0.08M | 0.26M | 0.66M | 1.39M | 1.83M | 1.88M | 3.12M | 3.95M | 4.00M | 3.82M | 3.50M | 2.99M | 2.47M | 2.02M | 1.64M | 1.32M | 1.06M | 1.11M | |||||
| Other Non Operating IncomeOther Non Op Inc. | 0.02M | 0.00M | 0.00M | -0.00M | -0.01M | -0.00M | -0.02M | -0.04M | -1.30M | -0.05M | 1.10M | 0.03M | 0.55M | 0.19M | -0.13M | -0.44M | -0.17M | 0.46M | -0.16M | ||||||
| Non Operating IncomeNon Op. Inc. | 0.03M | 0.07M | 0.08M | 0.26M | 0.66M | 1.38M | 1.83M | 1.87M | 3.08M | 1.99M | 2.90M | 3.84M | 2.50M | 2.44M | 1.57M | 0.80M | 0.06M | 0.06M | 0.41M | -0.16M | |||||
| Net income details | |||||||||||||||||||||||||
| EBT | -3.94M | -8.35M | -9.13M | -10.15M | -10.71M | -12.86M | -11.30M | -11.59M | -12.91M | -15.12M | -14.77M | -21.57M | -29.79M | -37.64M | -28.92M | -40.78M | -25.94M | -24.96M | -21.15M | -32.54M | |||||
| Profit After TaxPAT | -3.90M | -8.58M | -9.71M | -10.30M | -10.71M | -12.65M | -11.31M | -11.73M | -12.96M | -16.50M | -15.33M | -20.56M | -29.77M | -37.51M | -28.80M | -40.95M | -26.45M | -25.14M | -20.80M | -32.75M | |||||
| Income from Continuing OperationsIncome (Continuing) | -3.94M | -8.35M | -9.13M | -10.15M | -10.71M | -12.86M | -11.30M | -11.59M | -12.91M | -15.12M | -14.77M | -21.57M | -29.79M | -37.64M | -28.92M | -40.78M | -25.94M | -24.96M | -21.15M | -32.54M | |||||
| Consolidated Net IncomeConsol Net Inc. | -3.94M | -8.35M | -9.13M | -10.15M | -10.71M | -12.86M | -11.30M | -11.59M | -12.91M | -15.12M | -14.77M | -21.57M | -29.79M | -37.64M | -28.92M | -40.78M | -25.94M | -24.96M | -21.15M | -32.54M | |||||
| Income towards Parent CompanyParent Net Inc | -3.94M | -8.35M | -9.13M | -10.15M | -10.71M | -12.86M | -11.30M | -11.59M | -12.91M | -15.12M | -14.77M | -21.57M | -29.79M | -37.64M | -28.92M | -40.78M | -25.94M | -24.96M | -21.15M | -32.54M | |||||
| Net Income towards Common StockholdersNet Income | -3.94M | -8.35M | -9.13M | -10.15M | -10.71M | -12.86M | -11.30M | -11.59M | -12.91M | -15.12M | -14.77M | -21.57M | -29.79M | -37.64M | -28.92M | -40.78M | -25.94M | -24.96M | -21.15M | -32.54M | |||||
| Additional items | |||||||||||||||||||||||||
| EPS (Basic) | -0.10 | -0.42 | -0.23 | -0.25 | -0.26 | -0.32 | -0.28 | -0.28 | -0.24 | -0.31 | -0.25 | -0.36 | -0.50 | -0.63 | -0.48 | -0.67 | -0.43 | -0.41 | -0.33 | -0.45 | |||||
| EPS (Diluted) | -0.10 | -0.42 | -0.23 | -0.25 | -0.26 | -0.32 | -0.28 | -0.28 | -0.24 | -0.31 | -0.25 | -0.36 | -0.50 | -0.63 | -0.48 | -0.67 | -0.43 | -0.41 | -0.33 | -0.45 | |||||
| Shares Outstanding | 38.27M | 20.06M | 40.47M | 40.50M | 40.50M | 40.60M | 41.03M | 41.03M | 54.23M | 48.61M | 59.81M | 60.08M | 60.08M | 60.01M | 60.53M | 60.57M | 60.57M | 60.56M | 63.22M | 72.25M | |||||
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 38.27M | 20.06M | 40.47M | 40.50M | 40.50M | 40.60M | 41.03M | 41.03M | 54.23M | 48.61M | 59.81M | 60.08M | 60.08M | 60.01M | 60.53M | 60.57M | 60.57M | 60.56M | 63.22M | 72.25M | |||||
| EBITDA | -3.94M | -8.41M | -9.21M | -10.41M | -11.37M | -14.25M | -13.13M | -13.48M | -16.04M | -18.49M | -17.77M | -24.38M | -32.27M | -39.60M | -30.37M | -41.75M | -26.51M | -25.20M | -21.15M | -32.56M | |||||
| Interest ExpensesInt Expense | 0.02M | 0.58M | 1.00M | 1.00M | 1.03M | 1.04M | 1.02M | 1.05M | 1.07M | 1.09M | 1.07M | 1.09M |